Dear [enter recipient name],

My name is [Name], a representative for Azurity Pharmaceuticals, specializing in pediatric medicine.

I wanted to let you know that Xatmep® (methotrexate) oral solution is available for your patients with Acute Lymphoblastic Leukemia. It is also the first and only FDA-approved oral solution that is available.

Xatmep may benefit your patients:

- 2.5mg/mL provides easy dose titration as body surface area-based dosing is recommended.
- Ready-to-use Oral Solution with a sweet taste.
- Designed for the patient who is unable to swallow a tablet or has a fear of needles and prefers not to receive a shot.
- Provides patient convenience of being stable with options of being stored at room temperature for up to 60 days or refrigerated through the expiration date on the label.

I would like 10 minutes of your time to discuss Xatmep.

Thank you,

[INSERT YOUR NAME]
[INSERT YOUR TITLE]

Azurity Pharmaceuticals, Inc.
8 Cabot Road, Suite 2000
Woburn, MA 01801
T: Insert office number and extension
M: Insert mobile number if applicable

Committed to making a difference in patients' lives.

For more information, please visit Azurity.com

IMPORTANT SAFETY INFORMATION

WARNING: SEVERE TOXIC REACTIONS, INCLUDING EMBRYO-FETAL TOXICITY

See full prescribing information for complete boxed warning.

Methotrexate can cause the following severe or fatal adverse reactions.
Monitor closely and modify dose or discontinue methotrexate as appropriate.

- **Bone marrow suppression [*see Warnings and Precautions (5.1)*]**
- **Serious infections [*see Warnings and Precautions (5.2)*]**
- **Renal toxicity and increased toxicity with renal impairment [*see Warnings and Precautions (5.3)*]**
- **Gastrointestinal toxicity [*see Warnings and Precautions (5.4)*]**
- **Hepatic toxicity [*see Warnings and Precautions (5.5)*]**
- **Pulmonary toxicity [*see Warnings and Precautions (5.6)*]**
- **Hypersensitivity and dermatologic reactions [*see Warnings and Precautions (5.7)]***
- **Methotrexate can cause embryo-fetal toxicity, including fetal death. Use in pJIA is contraindicated in pregnancy. Consider the benefits and risks of XATMEP and risks to the fetus when prescribing XATMEP to a pregnant patient with a neoplastic disease. Advise females and males of reproductive potential to use effective contraception during and after treatment with XATMEP [*see Contraindications (4), Warnings and Precautions (5.9), Use in Specific Populations (8.1, 8.3)*].**

INDICATIONS

Xatmep is a folate analog metabolic inhibitor indicated for the:

- treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a multi-phase, combination chemotherapy maintenance regimen.
- management of pediatric patients with active polyarticular juvenile idiopathic arthritis (pJIA) who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs).

For Full Prescribing Information of Xatmep, please click here: Full Prescribing Information

For more information on Xatmep, please click here: Xatmep Website

XTM-27

Azurity Pharmaceuticals | 841 Woburn St., Wilmington, MA 01887 | Azurity.com